^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Urothelial Cancer
    Drug:trastuzumab rezetecan (SHR-A1811) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study

    Published date:
    10/16/2023
    Excerpt:
    SHR-A1811 had favorable antitumor activity and acceptable safety profile in heavily pretreated HER2-expressing/mutated advanced non-breast STs, including BTC, UC, GC/GEJA, and CRC.
    Trial ID:
    NCT04446260